Gilead Sciences, Inc. Essay
Gilead Sciences, Inc. was founded in Foster City, California in 1987, and it is one of largest research-based biopharmaceutical companies, with 8,000 employees across six continents. Gilead discovers, develops and commercializes innovative therapies in areas of unmet medical need. Gilead initially focused on developing therapies in HIV market. In September 1991, Gilead financed $20 million to keep the company going since they didn’t realize any revenue at the time. In January 1992, Gilead successfully launched its IPO on the Nasdaq exchange, and they sold approximately 5 million common shares for $86.25 million.
HIV: Viread, an oral drug to treat HIV infection in patients 2 years of age and older, was a major innovation in the HIV market in 2001, and it helped the company grow up in the US and Europe. In the next decade, Gilead introduced Truvada, Atripla, Complera and Stribuild in the market, and these medicines made Gilead the market leader in HIV therapies. In 2016, U.S. Food and Drug Administration approved Gilead’s 3 TAF-based single tablets for the treatment of HIV-1 infection, so we can forecast Gilead will lead the HIV treatment in the next decade.
Liver Diseases: In 2013, the FDA approved Sovaldi as an oral dual therapy for HCV treatment. Compared to previous treatments, Sovaldi- based drugs provides an extremely high cure rate with lower side effects. Sovaldi has become controversial due to its high…